Compare SNBR & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNBR | IXHL |
|---|---|---|
| Founded | 1987 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.7M | 63.3M |
| IPO Year | 1998 | 2024 |
| Metric | SNBR | IXHL |
|---|---|---|
| Price | $1.61 | $3.81 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 369.5K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,411,450,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.06 | $0.16 |
| 52 Week High | $13.94 | $6.39 |
| Indicator | SNBR | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 45.77 |
| Support Level | $1.06 | $0.34 |
| Resistance Level | $2.91 | $5.08 |
| Average True Range (ATR) | 0.39 | 0.36 |
| MACD | -0.10 | -0.13 |
| Stochastic Oscillator | 5.72 | 8.15 |
Sleep Number Corp is a designer, manufacturer, marketer, and retailer, which allows it to offer consumers high-quality, individualized sleep solutions and services. It also offers FlextFit adjustable bases, and Sleep Number pillows, sheets, and other bedding products. The company generates revenue by marketing its innovations directly to new and existing customers and selling products through its Stores, Online, Phone, Chat (Total Retail), and Other. It focuses on personalized sleep wellness, with mattresses designed to evolve with each sleeper to help them feel and perform well, featuring adjustable firmness, pressure-relieving support, and temperature-balancing comfort built into every mattress. Its products include mattresses, bundles, bedding, pillows, and furniture.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.